- Home
- UGI vs LEGN Comparison
UGI vs LEGN Comparison
Compare UGI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGI
- LEGN
- Stock Information
- Founded
- UGI 1940
- LEGN 2014
- Country
- UGI United States
- LEGN United States
- Employees
- UGI N/A
- LEGN N/A
- Industry
- UGI Natural Gas Distribution
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- UGI Utilities
- LEGN Health Care
- Exchange
- UGI Nasdaq
- LEGN Nasdaq
- Market Cap
- UGI 7.7B
- LEGN 5.4B
- IPO Year
- UGI N/A
- LEGN 2020
- Fundamental
- Price
- UGI $35.16
- LEGN $35.64
- Analyst Decision
- UGI Buy
- LEGN Strong Buy
- Analyst Count
- UGI 3
- LEGN 13
- Target Price
- UGI $31.33
- LEGN $75.17
- AVG Volume (30 Days)
- UGI 1.9M
- LEGN 2.0M
- Earning Date
- UGI 08-06-2025
- LEGN 08-08-2025
- Dividend Yield
- UGI 4.24%
- LEGN N/A
- EPS Growth
- UGI N/A
- LEGN N/A
- EPS
- UGI 2.46
- LEGN N/A
- Revenue
- UGI $7,318,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- UGI $6.56
- LEGN $65.49
- Revenue Next Year
- UGI $8.97
- LEGN $53.76
- P/E Ratio
- UGI $14.36
- LEGN N/A
- Revenue Growth
- UGI N/A
- LEGN 112.46
- 52 Week Low
- UGI $22.01
- LEGN $27.34
- 52 Week High
- UGI $36.74
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- UGI 46.55
- LEGN 57.79
- Support Level
- UGI $34.61
- LEGN $32.42
- Resistance Level
- UGI $36.45
- LEGN $36.91
- Average True Range (ATR)
- UGI 0.58
- LEGN 1.42
- MACD
- UGI -0.18
- LEGN 0.02
- Stochastic Oscillator
- UGI 37.09
- LEGN 67.58
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.